Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients

Lung, Respiratory and Thoracic Cancer
Do you want to read an article? Please log in or register.